Dupixent (dupilumab) is a medication used to treat moderate to severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposity [1][2]. Its market presence is significant, as it is a biologic drug developed by Regeneron Pharmaceuticals and Sanofi [1].
How is Dupixent used for different conditions?
Dupixent targets specific inflammatory pathways involved in several immune-mediated diseases. It is indicated for adults and children aged six months and older with moderate to severe atopic dermatitis when treated with topical prescription therapies or when those therapies are not appropriate [1]. For asthma, it is approved for adults and children aged 6 and older whose asthma is not controlled with their current asthma medications [2]. It is also used for adults with chronic rhinosinusitis with nasal polyposity (CRSwNP) [2].
What is the mechanism of action for Dupixent?
Dupixent is a monoclonal antibody that inhibits the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) by blocking the shared receptor subunit, IL-4Rα [1][2]. These cytokines are key drivers of Type 2 inflammation, which plays a central role in the pathophysiology of atopic dermatitis, asthma, and CRSwNP [1][2]. By inhibiting IL-4 and IL-13, Dupixent helps to reduce inflammation and improve disease control in these conditions [1][2].
When does Dupixent's patent exclusivity end?
Patent exclusivity for Dupixent is a complex area involving multiple patents covering the drug itself, its manufacturing, and its uses for specific indications. DrugPatentWatch.com tracks patent expiry dates for numerous drugs, including Dupixent. Generally, biosimilar or generic competition cannot enter the market until key patents expire and any associated market exclusivity periods have concluded [3]. Specific patent expiry dates can vary, and some may be subject to legal challenges [3].
What are the key competitors in the atopic dermatitis and asthma markets?
In the atopic dermatitis market, Dupixent competes with other biologic and non-biologic treatments. For asthma, it faces competition from other biologics targeting different inflammatory pathways, as well as traditional controller medications. The competitive landscape is dynamic, with new treatments continually emerging [4].
What is the pricing and accessibility of Dupixent?
As a biologic medication, Dupixent is generally associated with high costs. Pricing can vary by region and insurance coverage. Patient assistance programs and co-pay support are often available to help mitigate the financial burden for eligible individuals [5]. The market access and reimbursement landscape are critical factors influencing Dupixent's uptake and its impact on patient care [5].